MX341578B - Tratamiento de la osteoartritis y del dolor. - Google Patents

Tratamiento de la osteoartritis y del dolor.

Info

Publication number
MX341578B
MX341578B MX2013009130A MX2013009130A MX341578B MX 341578 B MX341578 B MX 341578B MX 2013009130 A MX2013009130 A MX 2013009130A MX 2013009130 A MX2013009130 A MX 2013009130A MX 341578 B MX341578 B MX 341578B
Authority
MX
Mexico
Prior art keywords
osteoarthritis
pain
treatment
binding proteins
multispecific
Prior art date
Application number
MX2013009130A
Other languages
English (en)
Other versions
MX2013009130A (es
Inventor
V Kamath Rajesh
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2013009130A publication Critical patent/MX2013009130A/es
Publication of MX341578B publication Critical patent/MX341578B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a una proteína de unión que se une tanto IL-1ß para usarse en el tratamiento de osteoartritis en un individuo que padece de osteoartritis, en donde la proteína de unión es una proteína de unión de dominio variable dual de inmunoglobulina (DVD-Ig) que se une tanto a IL-1? como a IL-1ß y trata la osteoartritis. Figura 1 y 2.
MX2013009130A 2011-02-08 2012-02-08 Tratamiento de la osteoartritis y del dolor. MX341578B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161440853P 2011-02-08 2011-02-08
PCT/US2012/024356 WO2012109373A2 (en) 2011-02-08 2012-02-08 Treatment of osteoarthritis and pain

Publications (2)

Publication Number Publication Date
MX2013009130A MX2013009130A (es) 2014-07-09
MX341578B true MX341578B (es) 2016-08-25

Family

ID=46600758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009130A MX341578B (es) 2011-02-08 2012-02-08 Tratamiento de la osteoartritis y del dolor.

Country Status (18)

Country Link
US (2) US8889130B2 (es)
EP (1) EP2672997A4 (es)
JP (2) JP5918275B2 (es)
KR (2) KR20130130825A (es)
CN (2) CN105749286A (es)
AU (2) AU2012214449B2 (es)
BR (1) BR112013020259A2 (es)
CA (1) CA2826564C (es)
CL (2) CL2013002298A1 (es)
CO (1) CO6751274A2 (es)
DO (2) DOP2013000178A (es)
IL (1) IL227771A0 (es)
MX (1) MX341578B (es)
RU (2) RU2563830C2 (es)
SG (1) SG192694A1 (es)
TW (2) TW201527322A (es)
UA (1) UA110049C2 (es)
WO (1) WO2012109373A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2470568A2 (en) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW202210507A (zh) 2012-11-01 2022-03-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
TW201536320A (zh) * 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP7053453B2 (ja) * 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
CN105106490A (zh) * 2015-09-02 2015-12-02 济南舜昊生物科技有限公司 一种治疗小儿髋关节积液的药物及其制备方法
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
EP3402530B1 (en) * 2016-01-13 2020-08-19 Genzyme Corporation Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CA3073137A1 (en) 2016-08-19 2018-02-22 Jeffrey S. Bartlett Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
JP6957614B2 (ja) * 2016-10-31 2021-11-02 コーロン ライフ サイエンス インコーポレイテッドＫｏｌｏｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅ， Ｉｎｃ． 疼痛を軽減または処置する組成物
CN106390099A (zh) * 2016-11-07 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种牙髓干细胞组合物及其应用
MX2019006614A (es) 2016-12-07 2019-10-15 Univ Florida Adnc del antagonista del receptor de interleucina-1.
US20180207267A1 (en) * 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
TWI671761B (zh) * 2017-05-01 2019-09-11 臺中榮民總醫院 脊椎關節炎患者疾病活動度電子病歷管理系統
CN113164430A (zh) 2018-06-03 2021-07-23 格莱科米拉治疗公司 用于在暴露于电离辐射和/或化学疗法之后预防严重健康后果和/或组织损伤的方法
CN110652502A (zh) * 2018-06-28 2020-01-07 复旦大学 一种靶向治疗类风湿关节炎的药物组合物
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116836291B (zh) * 2023-08-25 2023-11-07 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2286388C2 (ru) * 1988-05-27 2006-10-27 Амген Инк. Ингибитор интерлейкина-1, способ его получения, молекула днк, кодирующая ингибитор интерлейкина-1 и его предшественник
NZ503548A (en) * 1996-02-09 2001-09-28 Amgen Inc A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus
KR20020012320A (ko) * 1999-07-21 2002-02-15 그레고리 에이. 데모풀로스 동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법
HUP0301002A3 (en) 2000-06-29 2005-12-28 Abbott Lab Dual specificity antibodies and methods of making and using
WO2003073982A2 (en) * 2002-02-28 2003-09-12 Eli Lilly And Company Anti-interleukin-1 beta analogs
EP2213685B1 (en) * 2002-09-06 2013-11-27 Amgen Inc. Therapeutic anti-IL-1R1 monoclonal antibody
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
BRPI0506679A (pt) * 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
MX2007016032A (es) 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
JP2011523853A (ja) * 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
US20110165063A1 (en) 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
RU2011135768A (ru) 2009-01-29 2013-03-10 Эбботт Лэборетриз Белки, связывающие il-1
MX2011011670A (es) 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
CN102655880A (zh) 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
UY33386A (es) 2010-05-14 2011-12-30 Abbott Laboratoires Proteínas de unión a il-1
US9234249B2 (en) 2010-07-12 2016-01-12 Gen-Probe Incorporated Compositions and assays to detect swine H1N1 influenza A virus, seasonal H1 influenza A virus and seasonal H3 influenza A virus nucleic acids
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
CN104203278A (zh) * 2011-11-21 2014-12-10 阿布维公司 Il-1结合蛋白

Also Published As

Publication number Publication date
US8889130B2 (en) 2014-11-18
WO2012109373A3 (en) 2012-11-01
US20150050238A1 (en) 2015-02-19
CO6751274A2 (es) 2013-09-16
TW201527322A (zh) 2015-07-16
EP2672997A2 (en) 2013-12-18
KR20150080033A (ko) 2015-07-08
JP5918275B2 (ja) 2016-05-18
CA2826564C (en) 2018-05-15
CL2016000530A1 (es) 2016-12-02
TW201307389A (zh) 2013-02-16
MX2013009130A (es) 2014-07-09
CN105749286A (zh) 2016-07-13
UA110049C2 (uk) 2015-11-10
JP2014507434A (ja) 2014-03-27
IL227771A0 (en) 2013-09-30
CL2013002298A1 (es) 2014-08-08
CN103596591A (zh) 2014-02-19
RU2563830C2 (ru) 2015-09-20
US20120201781A1 (en) 2012-08-09
RU2015134562A (ru) 2018-12-24
SG192694A1 (en) 2013-09-30
CN103596591B (zh) 2016-08-24
CA2826564A1 (en) 2012-08-16
DOP2013000178A (es) 2014-06-30
WO2012109373A2 (en) 2012-08-16
AU2012214449A1 (en) 2013-05-02
RU2013141211A (ru) 2015-03-20
JP2016106086A (ja) 2016-06-16
AU2012214449B2 (en) 2016-07-07
NZ614207A (en) 2015-12-24
RU2015134562A3 (es) 2018-12-24
DOP2016000114A (es) 2016-06-15
TWI531377B (zh) 2016-05-01
EP2672997A4 (en) 2015-05-06
BR112013020259A2 (pt) 2018-05-15
KR20130130825A (ko) 2013-12-02
AU2016203917A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
IL285522A (en) Human monoclonal antibodies that bind to 2-masp and suppress 2-masp-dependent complement activation, methods for their production and uses thereof
PH12018500452A1 (en) Novel modulators and methods of use
PH12017501139A1 (en) Novel modulators and methods of use
EP2590671A4 (en) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AND USES THEREOF
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
PH12017500864A1 (en) Anti-notch1 antibodies
PH12014501108A1 (en) Anti-il-36r antibodies
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
RS20140202A1 (en) BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17
MX2013004979A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2013002270A (es) Inmonoglubinas de dominio variable doble y usos de las mismas.
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
MX2012005037A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
MX2015013170A (es) Proteinas de union especificas duales dirigidas contra tnf alpha.
IN2015DN00636A (es)
EA201101303A1 (ru) Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.

Legal Events

Date Code Title Description
FG Grant or registration